Journal
NPJ REGENERATIVE MEDICINE
Volume 6, Issue 1, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41536-021-00161-z
Keywords
-
Categories
Funding
- National Institute of Neurological Disorders and Stroke [1R01NS106907-01]
- Department of Defense [W81XWH-14-1-0572, W81XWH-16-1-0480]
- CoordenacAo de Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Government of Brazil
Ask authors/readers for more resources
Recent trials have shown that infusions of human umbilical cord-derived MSCs can reduce cytokine storm and lung damage in COVID-19 patients with ARDS. Further phase II/III trials are needed to confirm this efficacy and evaluate the potential of MSCs in preventing long-term COVID effects.
Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
